AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
NCT07611110 · VECTRA-01 Phase 3Recruiting
- Lead sponsor
- AstraZeneca (Industry)
- Enrollment
- 670 (estimated)
- Start date
- 4 May 2026
- Primary completion
- 4 Jun 2029 (estimated)
- Study completion
- 6 Jun 2030
- Last update posted
- 19 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Single
- Arms
- 2
Interventions
- Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]) Drug
- Cabazitaxel Drug
- Abiraterone Drug
- Enzalutamide Drug
- Apalutamide Drug
- Darolutamide Drug
- Deutenzalutamide Drug
- Radium-223 Drug
Conditions and primary outcome
- Metastatic Castration-resistant Prostate Cancer
Primary outcome
Radiographic Progression-Free Survival (rPFS) (From randomization until first radiographic progression per RECIST 1.1/PCWG3 by BICR, or death from any cause, whichever occurs first (up to approximately 33 months)); Overall Survival (OS) (From randomization until death from any cause (up to approximately 33 months))
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07611110.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07611110 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.